부산대학교 도서관

Summary:We have compared the efficacy of two PBSC mobilisation regimens, mini-ICE+filgrastim (second consolidation) and HiDAC+AMSA+filgrastim (third consolidation), in two consecutive cohorts of patients with AML CR1 receiving treatment according to a joint protocol. Group A: 18 patients, aged 41 (21-65) years, were mobilised with mini-ICE (idarubicin 8?mg/m2+cytarabine 800?mg/m2+etoposide 150?mg/m2 days 1-3) followed by filgrastim 300-480?µg once daily s.c. from day 11 after start of chemotherapy. Only four patients reached >5 CD34+ cells/µl blood (B-CD34+) and were able to undergo leukaphereses. Two out of 18 (11%) reached the defined target of ?2.0 × 106 CD34+ cells/kg after 1-3 leukaphereses. Group B: 20 patients, aged 50 (29-67) years, received HiDAC+AMSA (cytarabine 3?g/m2 b.i.d. days 1, 3, 5+amsacrine 150?mg/m2 q.d. days 2, 4) followed by filgrastim at a similar dose starting on day 7. A total of 18 patients reached B-CD34+ >5/µl and underwent PBSC harvesting, starting on day 23 (14-29) and yielding 4.0 (0.9-21) × 106 CD34+ cells/kg. Of 20 patients, 17 (85%) reached the defined target of ?2.0 × 106 CD34+ cells/kg after 1-3 leukaphereses. We conclude that HiDAC+AMSA+G-CSF - in contrast to mini-ICE+G-CSF - is an efficient regimen for mobilising PBSC in patients with AML CR1.Bone Marrow Transplantation (2003) 32, 1119-1124. doi:10.1038/sj.bmt.1704294 [ABSTRACT FROM AUTHOR]